1-6 of 6
Martin Carroll
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors

Gregory W. Schwartz, Bryan Manning, Yeqiao Zhou, Priya Velu, Ashkan Bigdeli, Rachel Astles, Anne W. Lehman, Jennifer J.D. Morrissette, Alexander E. Perl, Mingyao Li, Martin Carroll, Robert B. Faryabi
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 573–583.
https://doi.org/10.1158/1078-0432.CCR-18-0655
Published: 15 January 2019
View article titled, Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors
Open the PDF for Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors in another window
Includes: Supplementary data
Journal Articles

DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

Alison R. Sehgal, Phyllis A. Gimotty, Jianhua Zhao, Jing-Mei Hsu, Robert Daber, Jennifer D. Morrissette, Selina Luger, Alison W. Loren, Martin Carroll
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1614–1620.
https://doi.org/10.1158/1078-0432.CCR-14-0327
Published: 31 March 2015
View article titled, <em>DNMT3A</em> Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia
Open the PDF for <em>DNMT3A</em> Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia in another window
Includes: Supplementary data
Journal Articles

Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis

Anna Kalota, Grace R. Jeschke, Martin Carroll, Elizabeth O. Hexner
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1729–1739.
https://doi.org/10.1158/1078-0432.CCR-12-1907
Published: 02 April 2013
View article titled, Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
Open the PDF for Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis in another window
Includes: Supplementary data
Journal Articles

Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy

Alexander E. Perl, Margaret T. Kasner, Doris Shank, Selina M. Luger, Martin Carroll
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1716–1725.
https://doi.org/10.1158/1078-0432.CCR-11-2346
Published: 14 March 2012
View article titled, Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy
Open the PDF for Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

Alexander E. Perl, Margaret T. Kasner, Donald E. Tsai, Dan T. Vogl, Alison W. Loren, Stephen J. Schuster, David L. Porter, Edward A. Stadtmauer, Steven C. Goldstein, Noelle V. Frey, Sunita D. Nasta, Elizabeth O. Hexner, Jamil K. Dierov, Cezary R. Swider, Adam Bagg, Alan M. Gewirtz, Martin Carroll, Selina M. Luger
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6732–6739.
https://doi.org/10.1158/1078-0432.CCR-09-0842
Published: 02 November 2009
View article titled, A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
Open the PDF for A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia in another window
Journal Articles

A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Donald E. Tsai, Selina M. Luger, Charalambos Andreadis, Dan T. Vogl, Allison Kemner, Melissa Potuzak, Ami Goradia, Alison W. Loren, Alexander E. Perl, Stephen J. Schuster, David L. Porter, Edward A. Stadtmauer, Steven C. Goldstein, James E. Thompson, Cezary Swider, Adam Bagg, Anthony R. Mato, Martin Carroll
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (17): 5619–5625.
https://doi.org/10.1158/1078-0432.CCR-07-5185
Published: 02 September 2008
View article titled, A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
Open the PDF for A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia in another window
Includes: Supplementary data